Last updated: February 25, 2026
What is NDC 50268-0042?
NDC 50268-0042 corresponds to Rillasertib (ARQ 531), an investigational kinase inhibitor. Currently, it is in the early stages of clinical development for oncology indications, primarily targeting solid tumors.
Market Overview
Therapeutic Area and Demand
The drug belongs to the kinase inhibitor class, which has seen significant growth due to success in oncology. The global cancer therapy market reached $185 billion in 2022, with targeted therapies comprising approximately 60% of this figure. The demand for novel, effective kinase inhibitors remains high, driven by:
- Unmet needs in resistant or metastatic cancers.
- Expanding indications as clinical data emerges.
- Increasing adoption of personalized medicine.
Competitive Landscape
Key competitors include:
| Drug Name |
Indication |
Approval Status |
Annual Sales (2022) |
Key Features |
| Erlotinib (Tarceva) |
Non-small cell lung cancer |
Approved |
$1.2 billion |
EGFR inhibitor |
| Crizotinib (Zykadia) |
ALK-positive NSCLC |
Approved |
$960 million |
ALK inhibitor |
| Lapatinib (Tykerb) |
HER2-positive breast cancer |
Approved |
$460 million |
Dual EGFR/HER2 inhibitor |
NDC 50268-0042's potential market entrants will need to demonstrate superior efficacy and/or reduced adverse events to capture market share.
Regulatory Milestones & Timelines
- Currently in Phase I/II trials.
- Pending results to inform decision points for Phase III initiation.
- No approved indications or market authorization granted yet.
Price Projections
Factors Influencing Pricing
- Clinical efficacy data and safety profile.
- Competition from existing therapies.
- Manufacturing costs.
- Reimbursement landscape.
- Orphan designation or rare disease status can command premium pricing.
Historical Pricing Trends
Targeted oncology drugs in late-stage development or approved rarely exceed $10,000-$15,000 per month in treatment costs initially. Established drugs like Erlotinib are priced around $9,000 per month in the US.
Projected Pricing Range
| Scenario |
Estimated Monthly Price |
Assumptions |
| Conservative (generic consideration) |
$5,000 |
Pending clinical validation, moderate market entry pressure |
| Moderate (market entry with differentiation) |
$8,000 |
Demonstrates promising early efficacy, some differentiation |
| Premium (breakthrough designation) |
$12,000 |
Demonstrates significant clinical benefit, orphan status |
Revenue Projections
Assuming a launch in 2025 following clinical success:
| Assumption |
Market Penetration |
Estimated Annual Revenue (2025) |
| Low (10,000 patients, $5,000/month) |
20% |
$120 million |
| Mid (20,000 patients, $8,000/month) |
30% |
$576 million |
| High (50,000 patients, $12,000/month) |
50% |
$720 million |
These figures are speculative, reliant on actual approval, clinical data, and market uptake.
Strategic Considerations
- Advancing clinical data is critical for positioning.
- Securing favorable reimbursement pathways can influence pricing.
- Differentiation through reduced side effects or novel mechanisms offers a competitive edge.
- Collaboration or licensing deals with larger pharma firms could accelerate market access.
Key Takeaways
- NDC 50268-0042 is in early development, with limited public data on efficacy or safety.
- The oncology kinase inhibitor market is competitive but growing, with high unmet needs.
- Price points are projected between $5,000 and $12,000 monthly, heavily dependent on clinical results and perceived value.
- Revenue potential ranges from hundreds of millions to over a billion dollars annually, depending on market penetration and pricing.
FAQs
1. When could NDC 50268-0042 realistically reach market approval?
Potential approval could occur between 2025 and 2027 if clinical trials show positive results and regulatory pathways are favorable.
2. What factors will most influence its pricing strategy?
Efficacy, safety profile, competition, regulatory status, and reimbursement policies.
3. How does the competitive landscape impact potential market share?
Existing therapies with established efficacy may limit share unless NDC 50268-0042 demonstrates significant clinical advantages.
4. What regulatory designations could support premium pricing?
Orphan drug status, breakthrough therapy, and accelerated approval pathways.
5. What are key challenges for the commercial success of this drug?
Clinical efficacy demonstration, navigating reimbursement, and competing with established therapies.
References
- MarketResearch.com. (2022). Global Oncology Drugs Market.
- IQVIA. (2022). Prescription drug sales data.
- FDA. (2022). Oncology drug approval guidelines.
- EvaluatePharma. (2022). Oncology market trends.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies.
